AMPX

Amprius is executing the rare early-stage hat trick: revenue tripled to $71.9M (+205% YoY) on top of FY2024's +168%, gross profit jumped 145% to $8.26M, and the customer roster (AALTO Airbus, AeroVironment, BAE Systems, Teledyne FLIR, the U.S. Army, plus a DIU contract) anchors the silicon-anode story in defense/aviation demand that is real, NDAA-sensitive, and hard for foreign competitors to serve. The balance sheet backs the story: $90.5M cash, liabilities/equity of just 0.51x, and equity up 49% — this is not a company on the edge. Management's pivot to an asset-light contract-manufacturing model (the Amprius Korea Battery Alliance, >2.0 GWh of access with 'minimal capital investment') is the strategically correct response to its own capital constraints, and the decision to walk away from the Brighton, Colorado GWh plant validates that discipline.

The problem is that the market already knows all of this. At 25.8x trailing sales the stock discounts years of flawless execution, while the fundamentals underneath remain those of a deeply unprofitable early-stage manufacturer: an 11.5% gross margin, a -64.9% operating margin, a $44.0M net loss, -$31.1M of operating cash flow, and a -$218M accumulated deficit. Gross margin is improving but nowhere near the level where revenue growth converts to profit. The Brighton exit also carries a real near-term cost — a $19.1M impairment plus a $20.0M cash lease-termination payment that lands in Q1 2026, taking a sizeable bite out of the cash pile.